Wils P, Altwegg R, Buisson A, Vuitton L, et al. Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID. J Crohns Colitis 2025 Sep 10:jjaf166. doi: 10.1093.
PMID: 40929061